Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer

Jason S. Krumholtz, Jeff M. Michalski, Chandru Sundaram

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Health-related quality of life must be a factor when treatment options are discussed with a patient. Quality of life is measured by validated questionnaires that include generic and disease-targeted measures. Urinary and rectal symptoms and sexual function are evaluated after treatment for prostate cancer. Quality of life is adversely affected in the early post- brachytherapy period primarily by the urinary morbidity. Urinary symptoms peak 2 months after treatment and decline thereafter, although severe long- term urinary toxicity occurs in 3% to 12% of patients. Urinary symptoms are generally treated with alpha-blocker and anticholinergic drugs, but 2% to 5% of patients require transurethral resection of the prostate to relieve persistent obstruction. However, 6 months after treatment, overall satisfaction is excellent, and the majority of patients would recommend the procedure to a friend.

Original languageEnglish (US)
Pages (from-to)371-374
Number of pages4
JournalJournal of Endourology
Volume14
Issue number4
StatePublished - 2000
Externally publishedYes

Fingerprint

Brachytherapy
Prostatic Neoplasms
Quality of Life
Morbidity
Transurethral Resection of Prostate
Cholinergic Antagonists
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer. / Krumholtz, Jason S.; Michalski, Jeff M.; Sundaram, Chandru.

In: Journal of Endourology, Vol. 14, No. 4, 2000, p. 371-374.

Research output: Contribution to journalArticle

@article{e0e75e9defdd447ebd4a6ed122e86f40,
title = "Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer",
abstract = "Health-related quality of life must be a factor when treatment options are discussed with a patient. Quality of life is measured by validated questionnaires that include generic and disease-targeted measures. Urinary and rectal symptoms and sexual function are evaluated after treatment for prostate cancer. Quality of life is adversely affected in the early post- brachytherapy period primarily by the urinary morbidity. Urinary symptoms peak 2 months after treatment and decline thereafter, although severe long- term urinary toxicity occurs in 3{\%} to 12{\%} of patients. Urinary symptoms are generally treated with alpha-blocker and anticholinergic drugs, but 2{\%} to 5{\%} of patients require transurethral resection of the prostate to relieve persistent obstruction. However, 6 months after treatment, overall satisfaction is excellent, and the majority of patients would recommend the procedure to a friend.",
author = "Krumholtz, {Jason S.} and Michalski, {Jeff M.} and Chandru Sundaram",
year = "2000",
language = "English (US)",
volume = "14",
pages = "371--374",
journal = "Journal of Endourology",
issn = "0892-7790",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Health-related quality of life and morbidity in patients receiving brachytherapy for clinically localized prostate cancer

AU - Krumholtz, Jason S.

AU - Michalski, Jeff M.

AU - Sundaram, Chandru

PY - 2000

Y1 - 2000

N2 - Health-related quality of life must be a factor when treatment options are discussed with a patient. Quality of life is measured by validated questionnaires that include generic and disease-targeted measures. Urinary and rectal symptoms and sexual function are evaluated after treatment for prostate cancer. Quality of life is adversely affected in the early post- brachytherapy period primarily by the urinary morbidity. Urinary symptoms peak 2 months after treatment and decline thereafter, although severe long- term urinary toxicity occurs in 3% to 12% of patients. Urinary symptoms are generally treated with alpha-blocker and anticholinergic drugs, but 2% to 5% of patients require transurethral resection of the prostate to relieve persistent obstruction. However, 6 months after treatment, overall satisfaction is excellent, and the majority of patients would recommend the procedure to a friend.

AB - Health-related quality of life must be a factor when treatment options are discussed with a patient. Quality of life is measured by validated questionnaires that include generic and disease-targeted measures. Urinary and rectal symptoms and sexual function are evaluated after treatment for prostate cancer. Quality of life is adversely affected in the early post- brachytherapy period primarily by the urinary morbidity. Urinary symptoms peak 2 months after treatment and decline thereafter, although severe long- term urinary toxicity occurs in 3% to 12% of patients. Urinary symptoms are generally treated with alpha-blocker and anticholinergic drugs, but 2% to 5% of patients require transurethral resection of the prostate to relieve persistent obstruction. However, 6 months after treatment, overall satisfaction is excellent, and the majority of patients would recommend the procedure to a friend.

UR - http://www.scopus.com/inward/record.url?scp=0033931403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033931403&partnerID=8YFLogxK

M3 - Article

C2 - 10910154

AN - SCOPUS:0033931403

VL - 14

SP - 371

EP - 374

JO - Journal of Endourology

JF - Journal of Endourology

SN - 0892-7790

IS - 4

ER -